New B meningococcus vaccine shows promise in early-stage trial

The outcome of a trial published in Science Translational Medicine, shows encouraging results for a new vaccine targeting group B meningococcus (MenB), a significant cause of meningococcal disease worldwide, and establishes proof-of-concept in humans that a gene-based vaccine platform can induce protective antibody responses against bacteria.